Eterna Therapeutics
ERNA
A$2.75
Share price
-5.79%
Change (1 day)
-0.72%
Change (1 year)
Categories
Eterna Therapeutics (ERNA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$16.89 Million
According to Eterna Therapeutics's latest financial reports the company's total liabilities are A$16.89 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Eterna Therapeutics - Total liabilities on balance sheet (from 2020 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | A$5.73 M | -91.67% |
| 2023-12-31 | A$68.83 M | 360.52% |
| 2022-12-31 | A$14.94 M | 79.98% |
| 2021-12-31 | A$8.3 M | 21.71% |
| 2020-12-31 | A$6.82 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Baxter BAX | A$21.86 B | 129,339.55% | 🇺🇸 USA |
 Geron GERN | A$0.45 B | 2,572.47% | 🇺🇸 USA |
 Omeros Corporation OMER | A$0.68 B | 3,975.88% | 🇺🇸 USA |
 Sanofi SNY | A$95.42 B | 564,714.24% | 🇫🇷 France |
 Bio-Techne TECH | A$0.96 B | 5,588.38% | 🇺🇸 USA |
 Genetic Technologies GENE | A$4.47 M | -73.52% | 🇦🇺 Australia |
 Teva Pharmaceutical Industries TEVA | A$49.33 B | 291,897.46% | 🇮🇱 Israel |